Although we don’t have head-to-head trial comparison data for amikacin liposome inhalation suspension vs. IV amikacin, what do data reported in the CONVERT trial teach us about whether the liposomal construct represents a preferred strategy?

Although we don’t have head-to-head trial comparison data for amikacin liposome inhalation suspension vs. IV amikacin, what do data reported in the CONVERT trial teach us about whether the liposomal construct represents a preferred strategy?

CLICK HERE FOR CME CREDIT

Although we don’t have head-to-head trial comparison data for amikacin liposome inhalation suspension vs. IV amikacin, what do data reported in the CONVERT trial teach us about whether the liposomal construct represents a preferred strategy?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Stephen Ruoss, MD

Stephen Ruoss, MD

Clinical Chief, Pulmonary and Critical Care Medicine Division
Department of Medicine
Medical Director, Stanford Medical Center Respiratory Care Services, Stanford Medical Center
Medical Director, Stanford Medical Center Transfer Center,
Stanford Univer